---
title: Pembrolizumab and trastuzumab in combination with FLOT in the perioperative
  treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II
  trial of the AIO study group (AIO STO 0321)
date: '2023-11-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37909020/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231101180626&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'BACKGROUND: Esophagogastric adenocarcinoma (EGA) presents a substantial
  global health challenge as the number of cases continues to rise. The current standard
  approach for treating localized EGA involves a combination of triplet chemotherapy,
  which consists of a platinum compound, a fluoropyrimidine, and a taxane (known as
  FLOT), followed by surgery. In cases of metastatic EGA with HER2-positive status
  or in certain studies with localized EGA, the use of HER2-targeted antibodies such
  ...'
disable_comments: true
---
BACKGROUND: Esophagogastric adenocarcinoma (EGA) presents a substantial global health challenge as the number of cases continues to rise. The current standard approach for treating localized EGA involves a combination of triplet chemotherapy, which consists of a platinum compound, a fluoropyrimidine, and a taxane (known as FLOT), followed by surgery. In cases of metastatic EGA with HER2-positive status or in certain studies with localized EGA, the use of HER2-targeted antibodies such ...